Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Optomed

3.69 EUR

-0.41 %

5,577 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-0.41 %
-10.77 %
-1.60 %
-7.18 %
-20.92 %
-19.19 %
-12.47 %
-47.51 %
-19.54 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
79.06M EUR
Turnover
233.58K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Buy
Target price
Updated
07.11.2025
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
10.2.
2026

Annual report '25

6.5.
2026

Interim report Q1'26

8.5.
2026

General meeting '26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
2024 2025 Change Q1 3,3 4 +21,21% Q2 3,5 3,8 +8,57% Q1+Q2 6,8 7,8 +14,71% Q3 3,1 4,4 +41,94% Q4 5,1 4,4 -13,73% Q3+Q4 8,2 8,8 +7,32% Q1-Q4 15 16,5 +10,67 % The table shows that if Q4 revenue is the same as Q3, Optomed’s target of 10% growth will be reached. A positive earnings warning...
yesterday
by Koukku
26
Leana Wen, a member of Optomed’s board, interviewed CVS Health’s CMO at HLTH USA. The discussion focused on improving access to care, retail healthcare, and rapid diagnostic services — precisely the market that Optomed + AEYE are targeting in the USA. A positive sign: Optomed’s board...
12/12/2025, 6:27 PM
by Mr. Stock
26
A long segment has been released by Suther Health, and if you listen to it, Optomed and AI will definitely make a strong breakthrough. The train is moving fast, even though the stock price suggests otherwise:
12/12/2025, 9:49 PM
by Mr. Stock
25
I read Optomed’s response statement carefully now. A couple of points. Speed is emphasized, permit processes moving quickly, production ramped up quickly (good growth in demand then?) “In the current competitive environment, securing additional funding quickly is critical for the...
12/12/2025, 11:55 AM
by Puutaheinää
25
I agree. Now is the moment when a moat is being built in the United States. All efforts and resources should now be put into that. It has already been stated that the start has been slower than investors and the company itself expected. However, I am of the opinion that if and when...
12/12/2025, 12:31 PM
16
Both Aeye and Toku Clair will come to the Lumo camera. Aeye is much easier and faster to get. For Toku, we have to wait for Topcon to get approval first. Lumo Aeye will come first. A small addition : Here, we are first waiting for the Lumo 510k FDA approval to arrive. When that approval...
12/12/2025, 1:04 PM
by j.sälli
9
Lumo was supposed to include Toku’s algorithm. At least, Himberg has said so. Cardiovascular disease diagnostics raises Optomed’s potential to a new level.
12/12/2025, 12:19 PM
by Tobias
8
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.